<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3578">
  <stage>Registered</stage>
  <submitdate>19/06/2012</submitdate>
  <approvaldate>19/06/2012</approvaldate>
  <nctid>NCT01625390</nctid>
  <trial_identification>
    <studytitle>A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150</studytitle>
    <scientifictitle>A Phase 2/3, Multicenter, Open-label Clinical Study to Assess the Safety and Efficacy of BAY86-6150 in Subjects With Hemophilia A or B With Inhibitors, Composed of 2 Parts (A &amp; B). Part A: Sequential Cohorts of Four Dose Levels of the Modified rFVIIa BAY86-6150 Assessed in a Non-controlled Dose Response Design in Acutely Bleeding Subjects and for PK/ PD in an Intra-individual Crossover Design Compared With One Fixed Dose of Eptacog Alfa in Non-bleeding Subjects. Part B: Confirmatory Study to Further Investigate the Efficacy and Safety of BAY86-6150</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-000323-33</secondaryid>
    <secondaryid>15534</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemophilia A, Hemophilia B</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BAY86-6150
Treatment: drugs - eptacog alfa [activated]
Treatment: drugs - BAY86-6150

Experimental: Arm 1 - 

Active Comparator: Arm 2 - 

Experimental: Arm 3 - 


Treatment: drugs: BAY86-6150
Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.

Treatment: drugs: eptacog alfa [activated]
comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation

Treatment: drugs: BAY86-6150
Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Successful treatments of bleeding episodes. - A bleed was defined as successfully treated, if no administration of rescue medication was required.</outcome>
      <timepoint>10 hours after each bleed</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of successful treatments of bleeding episodes on subject level. - Proportion of successful treatments of bleeding episodes was calculated as number of bleeding episodes treated successfully - without rescue medication - divided by the total number of bleeding episodes on a dose level.</outcome>
      <timepoint>10 hours after each bleed</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to stop the bleed</outcome>
      <timepoint>10 hours after each bleed</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of injections needed to stop the bleeding episode.</outcome>
      <timepoint>10 hours after each bleed</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effectiveness of treatment as rated by the subject's assessment (very effective, effective, partially effective, not effective).</outcome>
      <timepoint>10 hours after each bleed</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participant's reported outcome as assessed by Euro QoL (EQ-5D).</outcome>
      <timepoint>14 days after last exposure to BAY86-6150</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participant's reported outcome as assessed by Brief Pain Inventory.</outcome>
      <timepoint>7 days after last exposure to BAY86-6150</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Participant's reported outcome as assessed by Work Productivity and Activity Impairment Questionaire.</outcome>
      <timepoint>14 days after last exposure to BAY86-6150</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male subjects

          -  12 to 62 years-of-age

          -  History of moderate or severe congenital hemophilia A or B with inhibitors to FVIII or
             FIX

          -  4 or more bleeding episodes in the last 6 months before enrollment.</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>62</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Clinically relevant coagulation disorder other than congenital hemophilia A or B with
             inhibitors

          -  History of coronary and/or peripheral atherosclerotic disease

          -  Disseminated intravascular coagulopathy, or stage 2 hypertension

          -  Angina pectoris

          -  Myocardial infarction

          -  Transient ischemic attack

          -  Stroke

          -  Congestive heart failure

          -  Thromboembolic event</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio de Janeiro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangdong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Tianjin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Atlántico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogotá</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus N</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden-Württemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rheinland-Pfalz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Punjab</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Pune</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>México D. F.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Oaxaca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>San Luis Potosí</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ekaterinburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Khabarovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Samara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Freestate</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Göteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Donetsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Odessa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Truro</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Haemophilia is a disorder, usually genetic, affecting mostly male individuals, in which one
      of the proteins needed to form blood clots (FVIII) is missing or not present in sufficient
      levels. In a person with haemophilia, the clotting process is much slower and the person
      experiences bleeding episodes that can result in serious problems and potential disability.

      The current haemophilia standard of care is to maintain FVIII activity level above 1%.
      Sometimes, patients can develop antibodies (so called "inhibitors") against FVIII and it is
      no longer effective at controlling bleeds. Bleeds in these patients are currently treated
      using other proteins involved in the clotting process.

      The purpose of this study is to investigate how effectively BAY86-6150 may stop acute bleeds
      in "inhibitor" patients. This study consists of two parts, A and B. The purpose of part A is
      to find the most effective yet tolerable out of four doses of BAY86-6150 with regard to
      efficacy and safety (dose-finding part). Part A is expected to last 9 - 29 months. The
      purpose of part B is to confirm efficacy and safety of the dose found in part A in all
      participating patients (confirmatory part). Part B is expected to last 12-32 months.

      Approximately 60 male subjects 12 to 62 years-of-age with moderate or severe haemophilia A or
      B, with inhibitors to FVIII or FIX, who have had 4 or more bleeding episodes in the last 6
      months, will participate in this study.

      Patient's bleeds will be treated with BAY86-6150 and with a rescue medication if no response
      is made to BAY86-6150. Patients will attend the treatment centre at regular intervals and be
      required to keep an electronic diary.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01625390</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>